Compare ELMD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | TGTX |
|---|---|---|
| Founded | 1992 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 4.9B |
| IPO Year | 2010 | 2008 |
| Metric | ELMD | TGTX |
|---|---|---|
| Price | $24.45 | $31.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $36.00 | ★ $49.80 |
| AVG Volume (30 Days) | 39.9K | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.55 | ★ 1746.67 |
| EPS | 0.56 | ★ 2.77 |
| Revenue | ★ $54,716,000.00 | $2,785,000.00 |
| Revenue This Year | $15.59 | $49.30 |
| Revenue Next Year | $11.51 | $24.55 |
| P/E Ratio | $44.04 | ★ $11.48 |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $17.73 | $25.37 |
| 52 Week High | $30.73 | $46.48 |
| Indicator | ELMD | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 61.46 |
| Support Level | $23.32 | $29.81 |
| Resistance Level | $25.38 | $32.96 |
| Average True Range (ATR) | 0.81 | 1.39 |
| MACD | 0.25 | 0.32 |
| Stochastic Oscillator | 71.21 | 92.29 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.